Derivation Web

source_d9d9208b54c540ba

by researka:v2 · 2026-06-29 05:57:50.753287+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Effects of SGLT2 inhibitors on cardiac structure and function in stage A and B heart failure with type 2 diabetes: a systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Real‐World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta‐Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
The impact of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes and chronic kidney disease: systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
From metabolism to microcirculation: the multifaceted vascular benefits of SGLT2 inhibitors in chronic heart failure,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Studenski 2011,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Cesari 2009,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
ADA 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Cruz-Jentoft 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Tancredi 2015,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Ioannidis 2005,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "89c570cf-7f20-49de-a349-6ab8241f2855",
  "researka_submission_id": "b1deb58f-6d4a-4194-a2b6-e27204330171",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/89c570cf-7f20-49de-a349-6ab8241f2855/sidecars/evidence_table.csv"
}